Loading...
Market
Agios' market cap at year-end 2024?
5
Resolution / Starting Odds
Below $5 Billion • 33%
$5 Billion to $10 Billion • 33%
Above $10 Billion • 33%
Stock market data from recognized financial services (e.g. Bloomberg, Yahoo Finance)
Story
Agios' Mitapivat Achieves Positive Phase 3 Results for Thalassemia, 30.4% Response, Stock Up 20%
Jun 3, 2024, 11:24 AM
Agios Pharmaceuticals announced on Monday that its drug Mitapivat achieved positive results in a Phase 3 study for treating transfusion-dependent alpha- or beta-thalassemia in adults. The study, named ENERGIZE-T, met its primary endpoint and all key secondary endpoints. The response rate for Mitapivat was 30.4% compared to 12.6% for the placebo, showing significant reduction in the need for blood transfusions. Following the announcement, Agios' stock price surged by 20%, reaching a 2.5-year high.
View original story
Similar markets
Less than $3 trillion • 25%
$3 trillion - $3.5 trillion • 25%
$3.5 trillion - $4 trillion • 25%
More than $4 trillion • 25%
Below $300B • 25%
$300B to $350B • 25%
$350B to $400B • 25%
Above $400B • 25%
Below $5 billion • 25%
$5 - $7.5 billion • 25%
$7.5 - $10 billion • 25%
Above $10 billion • 25%
Below $4 billion • 25%
$4 - $6 billion • 25%
$6 - $8 billion • 25%
Above $8 billion • 25%
Above $1 billion • 33%
Between $500 million and $1 billion • 33%
Below $500 million • 33%
Above $3.5 trillion • 33%
Between $3.0 trillion and $3.5 trillion • 33%
Below $3.0 trillion • 33%
Under $3 billion • 25%
$3 billion - $4 billion • 25%
$4 billion - $5 billion • 25%
Above $5 billion • 25%
Increase by over 10% • 33%
Decrease by over 10% • 33%
Remain within ±10% • 34%
Above $10 billion • 25%
$7 billion - $10 billion • 25%
$5 billion - $7 billion • 25%
Below $5 billion • 25%